Publications by authors named "A Siegemund"
Total Thrombus-Formation System in Patients with Peripheral Artery Disease.
Clin Appl Thromb Hemost
November 2024
Article Synopsis
- The Total Thrombus-formation Analysis System (T-TAS) is an automated tool designed to evaluate thrombus (blood clot) formation under simulated blood flow conditions, particularly in patients receiving antiplatelet therapy.
- This study examined T-TAS's effectiveness in detecting responses to dual antiplatelet therapy (DAPT) among 60 patients with peripheral artery disease (PAD) after a surgical procedure.
- Findings indicated that the platelet-chip (PL-chip) of T-TAS was able to identify low responders to DAPT more effectively than traditional aggregation tests, suggesting it could be a useful tool for monitoring treatment responses in PAD patients.
Article Synopsis
- The study investigates how well the diluted Russel's Viper Venom Time (dRVVT) tests can detect leftover activity from direct oral anticoagulants (DOAC) in patients, aiming to find an efficient screening method for this purpose.
- A total of 80 patients received one of four DOAC medications, and their blood was tested at various times to measure dRVVT alongside DOAC plasma levels.
- Results show that while dRVVT is very effective at indicating significant levels of DOAC, especially with the LA2 assay, it can help in emergency settings to quickly assess anticoagulant effects and make treatment decisions.
Introduction: Recombinant porcine factor VIII (rpFVIII) is a treatment option for break-through bleeds in patients with congenital haemophilia A with inhibitors (CHAwI) on emicizumab. However, there are limited data about the measurement of rpFVIII in the presence of emicizumab.
Aim: To analyse whether rpFVIII can be measured with a chromogenic assay with bovine component (bCSA) in plasma from CHAwI on emicizumab treatment.
Weight-adjusted dosing of tinzaparin for thromboprophylaxis in obese medical patients.
Res Pract Thromb Haemost
February 2023
Background: The optimal dose of tinzaparin for prophylaxis in obese medical patients is not well defined.
Objectives: To evaluate the anti-Xa activity in obese medical patients on tinzaparin prophylaxis adjusted for actual bodyweight.
Methods: Patients with a body mass index of ≥30 kg/m treated with 50 IU/kg tinzaparin once daily were prospectively included.